Meanwhile, PDCD4 also reduces the protein levels of pYB-1 and blocks the nuclear translocation of YB-1, resulting in the inability of YB-1 to bind to the promoter of MDR1 and reducing the resistance of cervical cancer to cisplatin [165]. Here, YBX1 is linked to cervical carcinoma.